Novartis AG Announces FDA Approval of Multiple Sclerosis (MS) Drug Kesimpta

Novartis AG announced multiple sclerosis (MS) drug KESIMPTA® (ofatumumab), which utilized Nf-L as secondary endpoint, was approved by the FDA.